Last reviewed · How we verify
PrEP
At a glance
| Generic name | PrEP |
|---|---|
| Also known as | polyethylene glycol, simethicone, metoclopramide, TDF/FTC, Descovy® 200/25mg (DIN= 02454424) |
| Sponsor | Centre for Infectious Disease Research in Zambia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacy-based PrEP Delivery in Kenya (NA)
- Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care (NA)
- The Trans-Led Care Study (NA)
- Mobile Vehicle-Based Delivery of Lenacapavir PrEP in Los Angeles County
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Evaluating the Healthy Families PrEP Program for Women at Risk for HIV (NA)
- Finishing HIV Project (NA)
- Resting-state Connectivity and Individual Differences in Affective Placebo Responsiveness
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PrEP CI brief — competitive landscape report
- PrEP updates RSS · CI watch RSS
- Centre for Infectious Disease Research in Zambia portfolio CI